High mortality at the beginning of the COVID-19 pandemic in a referral center in the metropolitan area of Mexico City

Authors

  • Alberto Ordinola Navarro Department of Infectious Disease, National Institute of Medical Science and Nutrition Salvador Zubiran, Mexico City, Mexico
  • Orestes de Jesús Cobos-Quevedo Department of Internal Medicine, Hospital de Especialidades "Dr. Antonio Fraga Mouret", Centro Médico Nacional La Raza del Instituto Mexicano del Seguro Social, Mexico City, Mexico
  • Javier Cervantes-Bojalil Department of Internal Medicine, Hospital de Especialidades "Dr. Antonio Fraga Mouret", Centro Médico Nacional La Raza del Instituto Mexicano del Seguro Social, Mexico City, Mexico
  • Esperanza Pérez Álvarez Department of Infectious Diseases, National Medical Center November 20 ISSTE, Mexico City, Mexico
  • Andrea González Gil Department of Internal Medicine, Hospital de Especialidades "Dr. Antonio Fraga Mouret", Centro Médico Nacional La Raza del Instituto Mexicano del Seguro Social, Mexico City, Mexico
  • Ana Lilia Peralta-Amaro Department of Internal Medicine, Hospital de Especialidades "Dr. Antonio Fraga Mouret", Centro Médico Nacional La Raza del Instituto Mexicano del Seguro Social, Mexico City, Mexico
  • Ana Laura Carrillo-González Department of Internal Medicine, Hospital de Especialidades "Dr. Antonio Fraga Mouret", Centro Médico Nacional La Raza del Instituto Mexicano del Seguro Social, Mexico City, Mexico
  • Arturo Olvera Acevedo Department of Internal Medicine, Hospital de Especialidades "Dr. Antonio Fraga Mouret", Centro Médico Nacional La Raza del Instituto Mexicano del Seguro Social, Mexico City, Mexico
  • Luis Francisco Pineda-Galindo Department of Internal Medicine, Hospital de Especialidades "Dr. Antonio Fraga Mouret", Centro Médico Nacional La Raza del Instituto Mexicano del Seguro Social, Mexico City, Mexico
  • Fernando Briceño-Moya Department of Internal Medicine, Hospital de Especialidades "Dr. Antonio Fraga Mouret", Centro Médico Nacional La Raza del Instituto Mexicano del Seguro Social, Mexico City, Mexico
  • Olga Lidia Vera-Lastra Department of Internal Medicine, Hospital de Especialidades "Dr. Antonio Fraga Mouret", Centro Médico Nacional La Raza del Instituto Mexicano del Seguro Social, Mexico City, Mexico
  • Bruno Ali Lopez Luis Department of Infectious Diseases, National Medical Center November 20 ISSTE, Mexico City, Mexico

DOI:

https://doi.org/10.3855/jidc.14389

Keywords:

COVID-19, epidemiology, Mexico, mortality, pandemic, SARS-CoV-2

Abstract

Introduction: There is limited information about the coronavirus disease 2019 (COVID-19) disease in Latin-American countries. Our objective was to describe the clinical characteristics and outcomes of COVID-19 patients in Mexico.

Methodology: We conducted a retrospective cohort study with 333 consecutive patients who were admitted to Hospital de Especialidades "Dr. Antonio Fraga Mouret" in Mexico City with COVID-19 between April 1, 2020, and June 30, 2020. Demographic, clinical, laboratory data, treatment details and 30-day outcomes were analyzed.

Results: The patients studied included 52% men (172/233) and the median age was 45 years. Up to 75% (250/333) of patients were classified as overweight or obese. There were 185 (56%) inpatients; 85% (158/185) were hospitalized in the general ward, and 15% (27/185) in the Intensive Care Unit (ICU). Laboratory measurements showed significant differences between inpatients and outpatients such as lymphocyte-count (median 0.8 vs 1.2×109/L, p < 0.001), LDH (median 650 vs 294 U/L, p < 0.001), CRP (median 147 vs 5 mg/L, p = 0.007), CK-MB (median, 15 vs 10 U/L, p = 0.008), ferritin (median, 860 vs 392 ng/mL, p = 0.02), and D-dimer (median, 780 vs 600 ng/mL, p = 0.15). These differences were seen between survivor and non-survivor patients as well. The rate of death in mechanically ventilated patients was 94% (67/71). Mortality at 30-day follow-up was 57% (105/185).

Conclusions: We observed that majority of the non-survivors were obese and young. Complications leading to death was observed in majority of the cases.

Downloads

Published

2022-08-30

How to Cite

1.
Ordinola Navarro A, Cobos-Quevedo O de J, Cervantes-Bojalil J, Pérez Álvarez E, González Gil A, Peralta-Amaro AL, Carrillo-González AL, Olvera Acevedo A, Pineda-Galindo LF, Briceño-Moya F, Vera-Lastra OL, Lopez Luis BA (2022) High mortality at the beginning of the COVID-19 pandemic in a referral center in the metropolitan area of Mexico City. J Infect Dev Ctries 16:1269–1277. doi: 10.3855/jidc.14389

Issue

Vol. 16 No. 08: August 2022

Section

Coronavirus Pandemic

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Crossref
Scopus
Google Scholar
Europe PMC